Matthew Lewis

My work involves developing high-throughput cell models to quickly test the efficacy of novel antisense oligonucleotides (ASOs) in reducing the production of mutant proteins that result in hypertrophic cardiomyopathy.

Before joining the Wood Group, I completed an Integrated Masters in Biology at the University of Oxford. For my master’s project, I investigated how a single mutation to the proofreading domain of DNA polymerase epsilon can result in the various cancers like the highly unusual giant-cell glioblastoma.